MACROGENICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MACROGENICS, INC. (MGNX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- MACROGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.97M, a 46.34% decline year-over-year.
- MACROGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.65M, a 39.67% decline year-over-year.
- MACROGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.55M, a 40.54% decline year-over-year.
- MACROGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.68M, a 45.03% decline year-over-year.
- MACROGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $14.29M, a 51.47% decline from fiscal 2024.
- MACROGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $29.44M, a 60.23% increase from fiscal 2023.
- MACROGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $18.37M, a 10.10% decline from fiscal 2022.
- MACROGENICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $20.44M, a 11.62% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.97M 10-Q · filed 2026-08-14 | $4.62M derived: sum of 2 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $2.65M 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | $14.29M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $3.55M 10-Q · filed 2025-11-12 | $7.23M derived: sum of 2 quarters · filed 2026-08-14 | $11.61M derived: sum of 3 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $3.68M 10-Q · filed 2026-08-14 | $8.06M derived: sum of 2 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $4.39M 10-Q · filed 2026-08-14 | ||||
| 2024-12-31 | $29.44M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $5.97M 10-Q · filed 2025-11-12 | $12.66M derived: sum of 2 quarters · filed 2025-11-12 | $18.17M derived: sum of 3 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $6.69M 10-Q · filed 2025-11-12 | $12.21M derived: sum of 2 quarters · filed 2025-11-12 | |||
| 2024-03-31 | $5.51M 10-Q · filed 2025-11-12 | ||||
| 2023-12-31 | $18.37M 10-K · filed 2026-03-09 | ||||
| 2023-09-30 | $4.75M 10-Q · filed 2024-11-05 | $9.18M derived: sum of 2 quarters · filed 2024-11-05 | $13.97M derived: sum of 3 quarters · filed 2024-11-05 | ||
| 2023-06-30 | $4.44M 10-Q · filed 2024-11-05 | $9.22M derived: sum of 2 quarters · filed 2024-11-05 | |||
| 2023-03-31 | $4.79M 10-Q · filed 2024-11-05 | ||||
| 2022-12-31 | $20.44M 10-K · filed 2025-03-20 | ||||
| 2022-09-30 | $5.08M 10-Q · filed 2023-11-06 | $10.43M derived: sum of 2 quarters · filed 2023-11-06 | $15.65M derived: sum of 3 quarters · filed 2023-11-06 | ||
| 2022-06-30 | $5.35M 10-Q · filed 2023-11-06 | $10.57M derived: sum of 2 quarters · filed 2023-11-06 | |||
| 2022-03-31 | $5.22M 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | $23.13M 10-K · filed 2024-03-07 | ||||
| 2021-09-30 | $6.31M 10-Q · filed 2022-11-03 | $12.42M derived: sum of 2 quarters · filed 2022-11-03 | $17.66M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $6.11M 10-Q · filed 2022-11-03 | $11.36M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $5.24M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $20.68M 10-K · filed 2023-03-15 | ||||
| 2020-09-30 | $5.80M 10-Q · filed 2021-11-02 | $10.93M derived: sum of 2 quarters · filed 2021-11-02 | $15.38M derived: sum of 3 quarters · filed 2021-11-02 | ||
| 2020-06-30 | $5.14M 10-Q · filed 2021-11-02 | $9.59M derived: sum of 2 quarters · filed 2021-11-02 | |||
| 2020-03-31 | $4.45M 10-Q · filed 2021-11-02 | ||||
| 2019-12-31 | $19.57M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $5.35M 10-Q · filed 2020-11-04 | $10.29M derived: sum of 2 quarters · filed 2020-11-04 | $14.04M derived: sum of 3 quarters · filed 2020-11-04 | ||
| 2019-06-30 | $4.93M 10-Q · filed 2020-11-04 | $8.68M derived: sum of 2 quarters · filed 2020-11-04 | |||
| 2019-03-31 | $3.75M 10-Q · filed 2020-11-04 | ||||
| 2018-12-31 | $16.52M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $4.52M 10-Q · filed 2019-11-06 | $8.73M derived: sum of 2 quarters · filed 2019-11-06 | $12.12M derived: sum of 3 quarters · filed 2019-11-06 | ||
| 2018-06-30 | $4.21M 10-Q · filed 2019-11-06 | $7.59M derived: sum of 2 quarters · filed 2019-11-06 | |||
| 2018-03-31 | $3.39M 10-Q · filed 2019-11-06 | ||||
| 2017-12-31 | $14.74M 10-K · filed 2020-02-25 | ||||
| 2016-12-31 | $12.16M 10-K · filed 2019-02-26 | ||||
| 2015-12-31 | $7.85M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $3.24M 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | $862.00K 10-K · filed 2016-02-29 | $862.16K 10-K · filed 2014-03-20 | |||
| 2012-12-31 | $838.00K 10-K · filed 2015-03-03 | $838.39K 10-K · filed 2014-03-20 | |||
| 2011-12-31 | $2.35M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |